Implicated in ARIA: Perivascular Macrophages and Microglia
These immune cells spew free radicals and inflammatory cytokines that damage blood vessels, contributing to edema and brain bleeds.
ALL NEWS
124 RESULTS
Sort By:
- Most Recent
- Most Commented
First Success Stories From Alzheimer’s Secondary Prevention Trial
Case studies from the Dominantly Inherited Alzheimer Network trial show amyloid immunotherapy can prevent tangles and cognitive decline in some mutation carriers.
Living Among Us: People Whose Alzheimer’s Is Already Being Prevented
On gantenerumab, some people with dominantly inherited AD mutations remain plaque- and tangle-free, and cognitively healthy, years after their expected age of onset.
World Trade Center Responders at Risk for Early Onset Dementia
People who sifted through piles of debris are nine times likelier to develop early onset, all-cause dementia than those exposed to little toxic dust.
Different Cellular Mechanisms in Familial and Sporadic Alzheimer’s?
A single-nuclei RNA-Seq study found more autophagy and chaperone gene expression in familial AD brain, more intense microglial activation in sporadic.
Under the Radar: APP Uppsala Fibrils Evade Microglia, PiB, Leqembi
In mice, these Aβ fibrils avoid riling microglia and astrocytes. They also evade both PiB and lecanemab.
Posterior Cortical Atrophy Is a Form of Young-Onset Alzheimer’s
Among 1,092 people with PCA, symptoms started around age 60, and 94 percent had amyloid plaques or neurofibrillary tangles.
First Evidence for Transmitted Alzheimer’s Disease?
Eight adults who, as children, had received growth hormone from cadavers developed cognitive problems and/or AD-like pathology in midlife.
Similar Risk Factors Found for Young- and Late-Onset Dementia
A U.K. Biobank analysis generated 15 risk factors for young-onset dementia. Many factors also correlated with late-onset disease.
Does One Copy of the Christchurch ApoE Variant Slow Alzheimer’s?
Twelve people heterozygous for this protective variant were still sharp seven years after their expected age of AD onset. One had fewer tangles than expected.
Cohort LEADS Toward Better Understanding of Sporadic Early Onset AD
First data from the Longitudinal Early-Onset Alzheimer’s Disease Study hints at what might cause this type of AD and how it unfolds.
Proteomics Discerns Sporadic from Familial Alzheimer’s Disease
While each disease features distinct proteomes in the brain, cerebrospinal fluid, and blood, some proteins overlap. They are more dysregulated in familial than in sporadic AD.
Reelin Variant Wards Off Dementia in Colombian Kindred Siblings
An amino acid change in this ApoE receptor-binding protein may have bestowed 20 years of resilience to a brother and sister carrying the presenilin Paisa mutation.
Crenezumab Secondaries Negative; Gantenerumab OLE Hints at Efficacy
At AAIC, secondary endpoint data from the API Colombian study showed trends favoring crenezumab, while people taking gantenerumab in open-label extensions declined more slowly than matched controls.
API Colombian Trial of Crenezumab Missed Primary Endpoints
Topline results showed no statistically significant slowing of decline on either of two primary endpoints. Trends across multiple endpoints favored crenezumab.
Current Filters
- Early Onset AD x